From New York’s bold $4.6 billion market forecast to the unlikely intersection of the Second Amendment and cannabis at the Supreme Court, the team explores the shifting tectonic plates of the U.S. industry. Are we witnessing the "locus of the c...

The federal government has finally acknowledged the "accepted medical use" of cannabis—but for millions of patients, the battle for true integration into the US healthcare system is just beginning. As we face a shifting regulatory landscape, is...

Chicago Atlantic's Steven Ernest, Head of Originations, pulls back the curtain on institutional cannabis lending — from how his firm evaluates operators and underwrites deals, to navigating distressed assets, ESOPs, and the murky road ahead for...

The 2026 Farm Bill draft is finally on the table, and while the "hemp loophole" remains untouched for now, the industry is already looking toward a post-cliff future. As big tobacco backs Canadian giants in Europe and stadiums open their doors ...

THC% might be the most overused number in cannabis—and it’s not helping consumers make better choices. In this episode, Ben nerds out with Dr. Riley Kirk on what actually drives effects, why “nose knows” matters, and how cannabis science can (a...